Parents' Perspectives on Diagnosis and Decision-Making regarding Ventilator Support in Children with SMA Type 1

Abstract

Spinal muscular atrophy (SMA) is a rare neuromuscular disorder with a broad clinical spectrum. The most severe phenotype—SMA type 1—is characterized by marked muscle weakness also affecting bulbar and respiratory function. Life expectancy of children with SMA type 1 is expected to be less than 2 years without ventilator support or disease-specific drug treatment. The aim of this study was to evaluate parents' perspectives on the process of decision-making regarding ventilator support in children with SMA type 1. Fourteen semi-structured interviews were performed with parents of children with SMA type 1 that decided either for or against ventilator support for their child. All children were diagnosed prior to the approval of SMA-specific drug treatment. Interviews were recorded and transcribed verbatim. Data analysis was performed using a qualitative content analysis approach according to Mayring. Parents experienced that they were not adequately informed about the disease and treatment options in first informed consent discussions. Especially regarding ventilator support, parents perceived that they were not offered ventilator support as an actual option for treatment. Regarding the decision of whether or not to offer ventilator support, parents reported that their attitude toward ventilator support and contact with other affected families or patient advocacy groups were more likely to influence the decision than the content of informed consent discussions with physicians. Our results underline the importance of an interdisciplinary team not only to provide parents with relevant information but also to consider the criteria of a patient-centered medicine.

Keywords

spinal muscular atrophy - ventilator support - decision-making - caregiver

Publication History

Received: 08 September 2021

Accepted: 24 January 2022

Article published online:
23 February 2022

• References

• 1 Lefebvre S, Bürglen L, Reboullet S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80 (01) 155-165
• 2 Farrar MA, Vucic S, Johnston HM, du Sart D, Kiernan MC. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J Pediatr 2013; 162 (01) 155-159
• 3 Zerres K, Rudnik-Schöneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 1995; 52 (05) 518-523
• 4 Schorling DC, Pechmann A, Kirschner J. Advances in treatment of spinal muscular atrophy—new phenotypes, new challenges, new implications for care. J Neuromuscul Dis 2020; 7 (01) 1-13
• 5 Pechmann A, Langer T, Schorling D. et al. Evaluation of children with SMA type 1 under treatment with nusinersen within the expanded access program in Germany. J Neuromuscul Dis 2018; 5 (02) 135-143
• 6 Pane M, Palermo C, Messina S. et al; Italian EAP working group. Nusinersen in type 1 SMA infants, children and young adults: preliminary results on motor function. Neuromuscul Disord 2018; 28 (07) 582-585
• 7 Farrar MA, Teoh HL, Carey KA. et al. Nusinersen for SMA: expanded access programme. J Neurol Neurosurg Psychiatry 2018; 89 (09) 937-942
• 8 Aragon-Gawinska K, Seferian AM, Daron A. et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: a cohort study. Neurology 2018; 91 (14) e1312-e1318
• 9 De Vivo DC, Bertini E, Swoboda KJ. et al; NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord 2019; 29 (11) 842-856
• 10 Vill K, Kölbel H, Schwartz O. et al. One year of newborn screening for SMA—results of a German Pilot Project. J Neuromuscul Dis 2019; 6 (04) 503-515
• 11 Wyatt KD, List B, Brinkman WB. et al. Shared decision making in pediatrics: a systematic review and meta-analysis. Acad Pediatr 2015; 15 (06) 573-583
• 12 Fiks AG, Jimenez ME. The promise of shared decision-making in paediatrics. Acta Paediatr 2010; 99 (10) 1464-1466
• 13 Pechmann A, Langer T, Kirschner J. Decision-making regarding ventilator support in children with SMA type 1—a cross-sectional survey among physicians. Neuropediatrics 2019; 50 (06) 359-366
• 14 Mayring P. Qualitative Content Analysis. Forum Qualitative Sozialforschung/Forum: Qualitative Social Research 2000;1(02. DOI: https://doi.org/10.17169/fqs-1.2.1089
• 15 Beernaert K, Lövgren M, Jeppesen J. et al. Parents' experiences of information and decision making in the care of their child with severe spinal muscular atrophy: a population survey. J Child Neurol 2019; 34 (04) 210-215
• 16 Qian Y, McGraw S, Henne J, Jarecki J, Hobby K, Yeh W-S. Understanding the experiences and needs of individuals with spinal muscular atrophy and their parents: a qualitative study. BMC Neurol 2015; 15: 217
• 17 Committee on Hospital Care and Institute For Patient- and Family-Centered Care. Patient- and family-centered care and the pediatrician's role. Pediatrics 2012; 129 (02) 394-404
• 18 O'Malley P, Mace SE, Brown K. American Academy of Pediatrics, American College of Emergency Physicians. Patient- and family-centered care and the role of the emergency physician providing care to a child in the emergency department. Ann Emerg Med 2006; 48 (05) 643-645
• 19 Lawton S, Hickerton C, Archibald AD, McClaren BJ, Metcalfe SA. A mixed methods exploration of families' experiences of the diagnosis of childhood spinal muscular atrophy. Eur J Hum Genet 2015; 23 (05) 575-580
• 20 Hjorth E, Kreicbergs U, Sejersen T, Lövgren M. Parents' advice to healthcare professionals working with children who have spinal muscular atrophy. Eur J Paediatr Neurol 2018; 22 (01) 128-134
• 21 Ryan MM. The use of invasive ventilation is appropriate in children with genetically proven spinal muscular atrophy type 1: the motion against. Paediatr Respir Rev 2008; 9 (01) 51-54 , discussion 55–56
• 22 Chen K-A, Widger J, Teng A, Fitzgerald DA, D'Silva A, Farrar M. Real-world respiratory and bulbar comorbidities of SMA type 1 children treated with nusinersen: 2-year single centre Australian experience. Paediatr Respir Rev 2020; 39: 54-60
• 23 Lavie M, Diamant N, Cahal M. et al. Nusinersen for spinal muscular atrophy type 1: real-world respiratory experience. Pediatr Pulmonol 2021; 56 (01) 291-298
• 24 Sansone VA, Pirola A, Albamonte E. et al. Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen. J Pediatr 2020; 219: 223-228.e4